Scott T. Rottinghaus - Aug 8, 2022 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role: Chief Medical Officer
Signature: /s/ Nathaniel S. Gardiner as attorney-in-fact
Stock symbol: ENTA
Transactions as of: Aug 8, 2022
Transactions value $: $0
Form type: 4
Date filed: 8/11/2022, 04:32 PM
Next filing: Nov 28, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENTA	Common Stock	Award	$0	+20K		$0.00	20K	Aug 8, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENTA	Stock Option (right to buy)	Award	$0	+75K		$0.00	75K	Aug 8, 2022	Common Stock	75K	$71.27	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (August 8, 2022). The restricted stock unit shares that vest will be issued on the first September 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.
F2	Twenty-five percent (25%) of such option will become exercisable on August 8, 2023 (the "Anniversary Date"), with the remainder to become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years from the Anniversary Date (in each case subject to the optionholder's continued employment).

Content

Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (August 8, 2022). The restricted stock unit shares that vest will be issued on the first September 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.

Twenty-five percent (25%) of such option will become exercisable on August 8, 2023 (the "Anniversary Date"), with the remainder to become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years from the Anniversary Date (in each case subject to the optionholder's continued employment).